Beiträge zum Schlagwort:

LungCancer_ESMO

IL-8 levels indicate tumour response early in anti-PD-1 therapy

Changes in serum IL-8 levels accurately reflect response to anti-PD-1 monoclonal antibodies in melanoma and NSCLC patients, shows new data.

Ramucirumab in combination with pembrolizumab shown to be promising in lung cancer

Promising clinical activity of ramucirumab used in combination with pembrolizumab paves the way for continued development in NSCLC, shows a phase I study.

Landmark trial results mean pembrolizumab could become a new option for patients with NSCLC (PD-L1 ≥50%)

The first trial studying pembrolizumab first line to platinum-based chemotherapy, KEYNOTE-024, found significant benefits in both PFS and OS. “In my opinion this was a landmark trial; this will change our treatment algorithms in patients with NSCLC,” Dr Martin Reck, Chief Oncology Physician, Lung Clinic Grosshansdorf, Germany, stated at the European Society for Medical Oncology Congress 2016.

Are immune checkpoint inhibitors only cost effective in NSCLC patients expressing PD-L1?

Immunotherapies have been a key focus of this year’s European Society for Medical Oncology Congress. But are they a cost effective option for all patient subtypes? Dr Ramon de Mello, Medical Oncologist and Professor of the Department of Biomedical Science, University of Algarve, Portugal, shared important research on the costs of immune checkpoint inhibitors for NSCLC, taking into account PD-L1 expression.

Nivolumab found to be a safe and feasible option in early stage NSCLC

Results presented at this year’s European Society for Medical Oncology Congress explored, for the first time, the use of nivolumab for stage I-IIIA NSCLC.